A clinical study of TG6002 and flucytosine in patients with colorectal cancer
收藏NIAID Data Ecosystem2026-03-11 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2538646
下载链接
链接失效反馈官方服务：
资源简介：
Primary objectives: Phase I:Determination of the maximum tolerated dose (MTD) or maximum feasible dose (MFD) and the recommended dose for the Phase IIa part (RP2D).Phase IIa:Determination of the preliminary efficacy of intrahepatic artery injection of TG6002 in combination with 5-FC.
Primary endpoints: Phase I:Dose-limiting toxicities, adverse events, serious adverse events, change in standard laboratory parameters and vital signs.Phase IIa:Disease control rate (DCR).
创建时间：
2019-10-15
